Corneal Dermoid
Conditions
Brief summary
To investigate the clinical efficacy of femtosecond laser-assisted autologous lamellar keratoplasty in treating corneal dermoids.
Interventions
PROCEDURELimbal autograft
Simple dermoid excision will be performed, followed by closure of the bare sclera and cornea by sutured femtosecond laser-assisted limbal autograft.
DEVICEFemtosecond laser
A commercial femtosecond laser to create a particular shaped graft for transplantation
Sponsors
Chunxiao Wang
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 5 to 35 years old, 2. Patients with limbal dermoid, scheduled for elective surgical excision, 3. The distance of less than 5 mm of lesion encroachment into the cornea, 4. The participant or their legal guardian has voluntarily chosen to participate in this study, has signed the informed consent form, and has demonstrated a high level of adherence to the study protocols and cooperation throughout the follow-up process.
Exclusion criteria
1. Keratoconus, 2. High myopia with a spherical equivalent of -15.0 D or less, 3. Ocular and facial active inflammation such as keratitis, trachoma, dacryocystitis, blepharitis, meibomian gland dysfunction, Sjogren's syndrome, cicatricial pemphigoid etc, 4. Corneal or ocular surface infection within 30 days prior to study entry, 5. Severe cicatricial eye disease, 6. Ocular surface malignancy, 7. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases, 8. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries, 9. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%, 10. Renal failure with creatinine clearance\< 25ml/min, 11. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L, 12. Platelet levels \< 150,000 or \> 450,000 per microlite, 13. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female), 14. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy, An international normalized ratio greater than 3 in patients accepting anticoagulant therapy, 15. Pregnancy (positive test) or lactation, 16. Active immunological diseases, 17. Signs of current infection, including fever and treatment with antibiotics, 18. Participation in another simultaneous medical investigation or clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Corneal Thickness | 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | To measure corneal thickness using anterior segment optical coherence tomography. |
| Corneal Transparency | Preoperatively, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | The transparency and appearance of the cornea will be observed using slit-lamp microscopy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best corrected visual acuity | Preoperatively, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | To measure best corrected visual acuity using ETDRS chart or Teller Acuity Cards. |
| Corneal power, astigmatism and aberration | Preoperatively, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | To measure the changes of corneal power, astigmatism and aberration using autorefractor keratometer and wavefront aberrometer respectively. |
| Cosmetic improvement | Preoperatively, 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | A grading system from 0 to 4 with slit-lamp photographs will be used to determine cosmetic result of each graft. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Restoration of corneal surface | 1 week, 1 month, 3 months, 6 months, 9 months, 12 months and 18 months postoperatively | Restoration of a completely epithelized, stable, and avascular corneal surface. |
Countries
China
Outcome results
None listed